Retrospective analysis found that the CRP/platelet ratio predicts survival in malignant lymphoma patients, indicating its significance in patient risk stratification.
Key Points
High C-reactive protein/platelet ratio correlates with poor overall survival in malignant lymphoma patients post-transplant.
At two years, overall survival was significantly lower at 30.1% for high CP ratio compared to 61.1% for low CP ratio.
Multivariate analysis showed high CP ratio as a strong predictor for worse outcomes, such as higher non-relapse mortality.
This study analyzed 311 patients undergoing allogeneic hematopoietic stem cell transplantation from multiple centers.